Literature DB >> 14686972

Topical carmustine (BCNU) in the treatment of mycosis fungoides.

Herschel S Zackheim1.   

Abstract

The University of California, San Francisco (UCSF), experience with topical carmustine (BCNU) in the treatment of approximately 200 patients with mycosis fungoides (MF) is summarized. Topical BCNU is an effective treatment for patch- and early plaque-stage MF. Side-effects are usually not a major deterrent to continuation of therapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14686972     DOI： 10.1111/j.1396-0296.2003.01641.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN： 1396-0296            Impact factor:   2.851


  8 in total

Review 1.  The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications.

Authors:  Ercole Mazzeo; Laura Rubino; Michela Buglione; Paolo Antognoni; Stefano Maria Magrini; Francesco Bertoni; Manuela Parmiggiani; Paola Barbieri; Filippo Bertoni
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-13

2.  Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides.

Authors:  John T O'Malley; Adele de Masson; Elizabeth L Lowry; Anita Giobbie-Hurder; Nicole R LeBoeuf; Cecilia Larocca; Ahmed Gehad; Edward Seger; Jessica E Teague; David C Fisher; Thomas S Kupper; Phillip M Devlin; Rachael A Clark
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

3.  Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.

Authors:  Christiane Querfeld; Steven T Rosen; Joan Guitart; Alfred Rademaker; David S Pezen; M Eileen Dolan; Joseph Baron; Daniel B Yarosh; Francine Foss; Timothy M Kuzel
Journal:  Clin Cancer Res       Date:  2011-07-11       Impact factor: 12.531

Review 4.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

5.  Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

Authors:  Narin Apisarnthanarax; Gary S Wood; Seth R Stevens; Sean Carlson; Derek V Chan; Lili Liu; Sarolta K Szabo; Pingfu Fu; Anita C Gilliam; Stanton L Gerson; Scot C Remick; Kevin D Cooper
Journal:  Arch Dermatol       Date:  2012-05

6.  How we treat mycosis fungoides and Sézary syndrome.

Authors:  Niloufer Khan; Sarah J Noor; Steven Horwitz
Journal:  Clin Adv Hematol Oncol       Date:  2021-09

Review 7.  Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.

Authors:  Taku Fujimura; Ryo Amagai; Yumi Kambayashi; Setsuya Aiba
Journal:  Pharmaceutics       Date:  2021-02-02       Impact factor: 6.321

8.  Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro.

Authors:  Catalina Silva-Hirschberg; Hannah Hartman; Samantha Stack; Steve Swenson; Radu O Minea; Michael A Davitz; Thomas C Chen; Axel H Schönthal
Journal:  Ther Adv Med Oncol       Date:  2019-12-06       Impact factor: 8.168
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.